Daily non-political popular news in brief.

Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire and New River Pharmaceuticals Inc. announce that their investigational ADHD treatment, lisdexamfetamine dimesylate, also known as NRP104 or LDX, yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 12 years who received six months of treatment in an open-label phase 3 study presented at a national meeting of child and adolescent psychiatrists.

Read more »

Keywords: lisdexamfetamine, dimesylate, adhd, phase, data, presented

« Previous | Next »

Similar news on "Lisdexamfetamine dimesylate in ADHD phase 3 data presented":

1. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
   05-23-2007 · EurekAlert!
   Shire plc announced positive results of four studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term and two long-term phase 3 studies, presented at the American Psychiatric Association annual meeting, demonstrated GXR significantly improved all core symptoms of ADHD in children aged 6 to 17 years. GXR is the first selective alpha-2A-adrenoceptor agonist tested in well-controlled studies as an ADHD treatment.
   Similar news · Read more »
   
2. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
   05-23-2007 · EurekAlert!
   Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
   Similar news · Read more »
   
3. Shire announces once-daily guanfacine extended release data in ADHD patients aged 6 to 17 years
   11-16-2006 · EurekAlert!
   Shire plc (Nasdaq: SHPGY, LSE: SHP, TSX: SHQ) announced that once-daily doses of the investigational medication guanfacine extended release (GXR, also referred to as SPD503), a selective alpha-2A-adrenoceptor agonist, significantly improved symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 17 years when used as a monotherapy, according to phase 3 trial results presented at the 2006 US Psychiatric & Mental Health Congress. Two additional studies also released at the meeting report the pharmacokinetic profile of GXR.
   Similar news · Read more »
   
4. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
5. Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
   06-04-2007 · EurekAlert!
   Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the impressive survival benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.
   Similar news · Read more »
   
6. Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients
   03-27-2007 · EurekAlert!
   Heart attack patients who received an new intravenous adult stem cell therapy, Provacel, experienced a lower number of adverse events, such as cardiac arrhythmias, and had significant improvements in heart, lung and global function compared to those who received a placebo, according to six-month Phase I study data presented at the American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans on March 25.
   Similar news · Read more »
   
7. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
   09-25-2007 · EurekAlert!
   New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with hormone-resistant prostate cancer, could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo.
   Similar news · Read more »
   
8. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
   10-04-2007 · EurekAlert!
   MedImmune, Inc. today announced two important studies being presented at the Infectious Diseases Society of America Annual Meeting regarding respiratory syncytial virus. Data pertain to safety and immunogenicity of motavizumab, an investigational anti-RSV MAb, and a nationwide surveillance program evaluating the variability of the RSV season in the United States.
   Similar news · Read more »
   
9. Survival data presented from phase II study of hormone-resistant prostate cancer patients
   09-25-2007 · EurekAlert!
   The results from a randomized, double-blind, placebo-controlled, Phase II study of ZD4054 -- a specific endothelin A receptor antagonist -- were delivered today at the 14th European Congress of Clinical Oncology (ECCO, 23-27 Sept., Barcelona). The data presented today for ZD4054, an investigational compound in development for the treatment of men with hormone-resistant prostate cancer, showed no differences in progression-free survival but did report encouraging overall survival data.
   Similar news · Read more »
   
10. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
    10-15-2007 · EurekAlert!
    Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
    Similar news · Read more »